RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
26
07
2023
accepted:
30
09
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
aheadofprint
Résumé
Cancer driver mutations often show distinct temporal acquisition patterns, but the biological basis for this, if any, remains unknown. RAS mutations occur invariably late in the course of acute myeloid leukaemia, upon progression or relapsed/refractory disease
Identifiants
pubmed: 39478230
doi: 10.1038/s41586-024-08137-x
pii: 10.1038/s41586-024-08137-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209–2221 (2016).
pubmed: 27276561
pmcid: 4979995
doi: 10.1056/NEJMoa1516192
Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–3627 (2013).
pubmed: 24030381
doi: 10.1182/blood-2013-08-518886
Miles, L. A. et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature 587, 477–482 (2020).
pubmed: 33116311
pmcid: 7677169
doi: 10.1038/s41586-020-2864-x
Morita, K. et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat. Commun. 11, 5327 (2020).
pubmed: 33087716
pmcid: 7577981
doi: 10.1038/s41467-020-19119-8
Menssen, A. J. et al. Convergent clonal evolution of signaling gene mutations is a hallmark of myelodysplastic syndrome progression. Blood Cancer Discov. 3, 330–345 (2022).
pubmed: 35709710
pmcid: 9338759
doi: 10.1158/2643-3230.BCD-21-0155
Makishima, H. et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat. Genet. 49, 204–212 (2017).
pubmed: 27992414
doi: 10.1038/ng.3742
Levine, A. J., Jenkins, N. A. & Copeland, N. G. The roles of initiating truncal mutations in human cancers: the order of mutations and tumor cell type matters. Cancer Cell 35, 10–15 (2019).
pubmed: 30645969
pmcid: 6376970
doi: 10.1016/j.ccell.2018.11.009
Kent, D. G. & Green, A. R. Order matters: the order of somatic mutations influences cancer evolution. Cold Spring Harb. Perspect. Med. 7, a027060 (2017).
pubmed: 28096247
pmcid: 5378012
doi: 10.1101/cshperspect.a027060
Prior, I. A., Hood, F. E. & Hartley, J. L. The frequency of Ras mutations in cancer. Cancer Res. 80, 2969–2974 (2020).
pubmed: 32209560
pmcid: 7367715
doi: 10.1158/0008-5472.CAN-19-3682
Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994).
pubmed: 7509044
doi: 10.1038/367645a0
Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737 (1997).
pubmed: 9212098
doi: 10.1038/nm0797-730
Bennett, J. M. et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br. J. Haematol. 33, 451–458 (1976).
pubmed: 188440
doi: 10.1111/j.1365-2141.1976.tb03563.x
Shlush, L. I. et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 547, 104–108 (2017).
pubmed: 28658204
doi: 10.1038/nature22993
Zeng, A. G. X. et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat. Med. 28, 1212–1223 (2022).
pubmed: 35618837
doi: 10.1038/s41591-022-01819-x
Ng, S. W. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433–437 (2016).
pubmed: 27926740
doi: 10.1038/nature20598
Konopleva, M. et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6, 1106–1117 (2016).
pubmed: 27520294
pmcid: 5436271
doi: 10.1158/2159-8290.CD-16-0313
DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617–629 (2020).
pubmed: 32786187
doi: 10.1056/NEJMoa2012971
Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202–208 (2013).
pubmed: 23291630
doi: 10.1038/nm.3048
DiNardo, C. D. et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 7, e724–e736 (2020).
pubmed: 32896301
pmcid: 7549397
doi: 10.1016/S2352-3026(20)30210-6
Wei, A. H. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135, 2137–2145 (2020).
pubmed: 32219442
pmcid: 7290090
doi: 10.1182/blood.2020004856
Kadia, T. M. et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 40, 3848–3857 (2022).
pubmed: 35704787
pmcid: 9671758
doi: 10.1200/JCO.21.02823
Pei, S. et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10, 536–551 (2020).
pubmed: 31974170
pmcid: 7124979
doi: 10.1158/2159-8290.CD-19-0710
Kuusanmaki, H. et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica 105, 708–720 (2020).
pubmed: 31296572
pmcid: 7049363
doi: 10.3324/haematol.2018.214882
Zhang, H. et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat. Cancer 1, 826–839 (2020).
pubmed: 33123685
pmcid: 7591155
doi: 10.1038/s43018-020-0103-x
Stahl, M. et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 5, 1552–1564 (2021).
pubmed: 33687434
pmcid: 7948282
doi: 10.1182/bloodadvances.2020003734
Waclawiczek, A. et al. Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine/venetoclax. Cancer Discov. 13, 1408–1427 (2023).
pubmed: 36892565
pmcid: 10236156
doi: 10.1158/2159-8290.CD-22-0939
Wang, T. et al. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell 28, 1074–1089 e1077 (2021).
pubmed: 33571445
pmcid: 8178190
doi: 10.1016/j.stem.2021.01.011
Kotini, A. G. et al. Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. Cell Stem Cell 20, 315–328 e317 (2017).
pubmed: 28215825
pmcid: 5337161
doi: 10.1016/j.stem.2017.01.009
Corces, M. R. et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat. Genet. 48, 1193–1203 (2016).
pubmed: 27526324
pmcid: 5042844
doi: 10.1038/ng.3646
Kotini, A. G. et al. Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukemia. Blood Cancer Discov. 4, 318–335 (2023).
pubmed: 37067914
doi: 10.1158/2643-3230.BCD-22-0167
Nam, A. S. et al. Somatic mutations and cell identity linked by genotyping of transcriptomes. Nature 571, 355–360 (2019).
pubmed: 31270458
pmcid: 6782071
doi: 10.1038/s41586-019-1367-0
Velten, L. et al. Human haematopoietic stem cell lineage commitment is a continuous process. Nat. Cell Biol. 19, 271–281 (2017).
pubmed: 28319093
doi: 10.1038/ncb3493
Lasry, A. et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer 4, 27–42 (2023).
pubmed: 36581735
Bernard, E. et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 1, EVIDoa2200008 (2022).
pubmed: 38319256
doi: 10.1056/EVIDoa2200008
Matarraz, S. et al. Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry. Cytometry B Clin. Cytom. 92, 218–227 (2017).
pubmed: 26282340
doi: 10.1002/cyto.b.21219
Kotini, A. G. et al. Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nat. Biotechnol. 33, 646–655 (2015).
pubmed: 25798938
doi: 10.1038/nbt.3178
Bhatt, S. et al. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. Cancer Cell 38, 872–890 e876 (2020).
pubmed: 33217342
doi: 10.1016/j.ccell.2020.10.010
Pan, R. et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4, 362–375 (2014).
pubmed: 24346116
doi: 10.1158/2159-8290.CD-13-0609
Maiti, A. et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106, 894–898 (2021).
pubmed: 32499238
doi: 10.3324/haematol.2020.252569
Schulze, C. J. et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science 381, 794–799 (2023).
pubmed: 37590355
pmcid: 10474815
doi: 10.1126/science.adg9652
Holderfield, M. et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature 629, 919–926 (2024).
Pearce, D. J. et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107, 1166–1173 (2006).
pubmed: 16234360
pmcid: 1895911
doi: 10.1182/blood-2005-06-2325
Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 1086–1093 (2011).
pubmed: 21873988
doi: 10.1038/nm.2415
Pei, S. et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 13, 2032–2049 (2023).
pubmed: 37358260
pmcid: 10527971
doi: 10.1158/2159-8290.CD-22-1297
Zhang, Q. et al. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct. Target Ther. 7, 51 (2022).
pubmed: 35185150
pmcid: 8858957
doi: 10.1038/s41392-021-00870-3
Carter, B. Z. et al. Maximal activation of apoptosis signaling by cotargeting antiapoptotic proteins in BH3 mimetic-resistant AML and AML stem cells. Mol. Cancer Ther. 21, 879–889 (2022).
pubmed: 35364607
pmcid: 9167707
doi: 10.1158/1535-7163.MCT-21-0690
Caenepeel, S. et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 8, 1582–1597 (2018).
pubmed: 30254093
doi: 10.1158/2159-8290.CD-18-0387
Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275–291 (2014).
pubmed: 24607403
doi: 10.1016/j.stem.2014.02.006
Wang, J. C. & Dick, J. E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494–501 (2005).
pubmed: 16084092
doi: 10.1016/j.tcb.2005.07.004
Song, W. J. et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet. 23, 166–175 (1999).
pubmed: 10508512
doi: 10.1038/13793
Krutein, M. C. et al. Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation. Blood Adv. 5, 687–699 (2021).
pubmed: 33560381
pmcid: 7876894
doi: 10.1182/bloodadvances.2020002709
Chang, C. J. et al. Dissecting the contributions of cooperating gene mutations to cancer phenotypes and drug responses with patient-derived iPSCs. Stem Cell Rep. 10, 1610–1624 (2018).
doi: 10.1016/j.stemcr.2018.03.020
Gonzalez, F. et al. An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell 15, 215–226 (2014).
pubmed: 24931489
pmcid: 4127112
doi: 10.1016/j.stem.2014.05.018
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
pubmed: 29608179
pmcid: 6700744
doi: 10.1038/nbt.4096
Angerer, P. et al. destiny: diffusion maps for large-scale single-cell data in R. Bioinformatics 32, 1241–1243 (2016).
pubmed: 26668002
doi: 10.1093/bioinformatics/btv715
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).
pubmed: 31740819
pmcid: 6884693
doi: 10.1038/s41592-019-0619-0
Tsoucas, D. et al. Accurate estimation of cell-type composition from gene expression data. Nat. Commun. 10, 2975 (2019).
pubmed: 31278265
pmcid: 6611906
doi: 10.1038/s41467-019-10802-z
Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424–447 (2017).
pubmed: 27895058
pmcid: 5291965
doi: 10.1182/blood-2016-08-733196
Xu, J., Jorgensen, J. L. & Wang, S. A. How do we use multicolor flow cytometry to detect minimal residual disease in acute myeloid leukemia? Clin. Lab. Med. 37, 787–802 (2017).
pubmed: 29128069
doi: 10.1016/j.cll.2017.07.004